BioInvent International AB has appointed Björn Frendeus as vice president of preclinical research responsible for overseeing the company’s research up to preclinical safety testing. He will report to the chief executive, Svein Mathisen. Mr Frendeus has a PhD in immunology from Lund University.
Based in Lund, Sweden, BioInvent in developing antibody drugs in the areas of thrombosis, cancer and atherosclerosis.
Copyright 2009 Evernow Publishing Ltd